 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
China Biologic Products (CBPO) is a biopharmaceutical company.
The firm is engaged in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers.
It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors.
In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative heating; and Human coagulation factor VIII for the treatment of coagulopathie, such as hemophilia A.
The companys products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; immune globulin intravenous, Caprylate/Chromatography virus filtration; and human antithrombin III. It distributes its products directly or through distributors.
Shares are in the process of moving higher out of a bullish "cup & handle" and higher share prices are expected for this stock.
52-Week Trading Range: $26.66 - $61.33
Entry Point: $60.00
Stop Loss: $57.00
Target Price: $66.00
CBPO reached our target price. Closed at $66.00
